TCRT — Alaunos Therapeutics, Inc. Common Stock
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 1
- Website: https://www.alaunos.com
Latest SEC filings for TCRT
- 8-K — 2026-10-23
- 8-K — 2026-09-22
- 424B3 — 2026-09-21
- 8-K — 2026-09-17
- 10-Q — 2026-08-14
- 8-K — 2026-06-29
- 8-K — 2026-05-26
- 8-K — 2026-05-18
- 10-Q — 2026-05-15
- 10-K/A — 2026-04-30
Latest TCRT news
- — Alaunos Therapeutics Reports Encouraging Early Obesity Drug Results - Stocktwits (Stocktwits)
- — Most Active Stocks in Today's US Session - ChartMill (ChartMill)
- — 12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga (Benzinga)
- — Unusual Volume Movers: WFF, TGL, XXII and HODO Among US-Listed Stocks in Heavy Trading - ChartMill (ChartMill)
- — TCRT Stock Explodes As Alaunos Seals Velaris Deal And $350M Raise - StocksToTrade (StocksToTrade)
- — TCRT Stock Explodes As Alaunos Lands $350M Velaris Deal - Timothy Sykes (Timothy Sykes)
- — TCRT Stock Explodes As Alaunos Lands $350M Velaris Deal - www.timothysykes.com (www.timothysykes.com)
- — US Gap-Up and Gap-Down Stocks in the October 16, 2026 Session - ChartMill (ChartMill)
- — TCRT Stock Explodes As Velaris Deal And $350M Cash Shift The Story - Timothy Sykes (Timothy Sykes)
- — TCRT Stock Explodes As Velaris Deal And $350M Cash Shift The Story - www.timothysykes.com (www.timothysykes.com)
Educational tool only — not investment advice.